Put Arrhythmia Warnings for Lamotrigine in Context
June 2021
A new FDA warning will spur questions about the risk of serious arrhythmias with lamotrigine (Lamictal).
Labeling now cautions to weigh lamotrigine risks and benefits in patients with ischemic CV damage (prior MI, etc)...structural or functional disease (heart failure, AV block, etc)...or multiple CV risks.
It stems from lab data showing that lamotrigine’s effects on cardiac sodium channels could widen the QRS interval...and from case reports linking lamotrigine to ECG changes or cardiac arrest.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote